SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

Go back to SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
(NASDAQ: SPRC) Delayed: 4.51 +0.06 (1.35%)
Previous Close $4.45    52 Week High
Open $4.48    52 Week Low
Day High $4.64    P/E N/A 
Day Low $4.45    EPS
Volume 3,058